Genmab — December 2012
-
competion fra GA101
-
det er ikke en concern for genmab
-
ofa consistently outperformed GA101
-
safety profile ser dårlig ud for ga101
-
og ofa er hurtigere ude
-
og vi når endpoint
-
vi er mere elegante end de andre, inspireret af naturen
-
hexa aktiveres først når den er docket
-
nordea spørgsmål
-
er reduceringen effekt af flere indtægter eller lavere omkostninger
-
hvornår ser vi den profitable?
-
revenue bliver forøget
-
mest fra daratumumab
-
så der ligger deferred fra janssen
-
full year reimbursement fra janssen
-
og så er der duobody
-
hahaha
-
han vil ikke have flere milestones
-
i 2012
-
han tror på stigende udgifter i omkostninger
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind